Please login to the form below

Not currently logged in
Email:
Password:

CGRP antagonists

This page shows the latest CGRP antagonists news and features for those working in and with pharma, biotech and healthcare.

Teva buys into Heptares oral CGRP programme for migraine

Teva buys into Heptares oral CGRP programme for migraine

The agreement - which includes a $10m upfront payment from Teva to Heptares - covers a series of small-molecule calcitonin gene-related peptide (CGRP) antagonists, all of which are currently in preclinical ... CGRP is a neurotransmitter that is elevated

Latest news

  • Allergan stumps up $375m for bolt-on acquisitions Allergan stumps up $375m for bolt-on acquisitions

    The deal with Merck covers MK-1602 and MK-8031, both of which are orally active, small molecule CGRP antagonists for the acute treatment of migraines. ... They are in a race to market with other CGRP antagonists such as Teva's TEV-48125 - which is also

  • Migraine drugs' headache Migraine drugs' headache

    CGRP can also cause the release of inflammatory agents from meningeal mast cells. ... It is thought that CGRP receptor antagonists could alleviate migraine symptoms by blocking these pathophysiological activities of CGRP.

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Deal Watch November 2015 Deal Watch November 2015

    455. Heptares. Teva. Licence drug-discovery agreement. Small molecule calcitonin gene-related peptide (CGRP) antagonists for migraine.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Digitas Health

Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics